Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atsuko Fujihara

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
European Journal of Radiology|February 15, 2025
Temporal Evolution of multiparametric magnetic resonance imaging findings following lesion-targeted focal microwave tissue coagulation for localized prostate cancerBunta Tokuda, Kaori Yamada, Nana Kozawa, et al.
Clinical and Translational Radiation Oncology|October 26, 2020
Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderlyHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Cancers|July 24, 2021
Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk FactorsHideya Yamazaki, Gen Suzuki, Koji Masui, et al.
Scientific Reports|April 24, 2023
Novel device for dividing core needle biopsy specimens to provide paired mirror image-like tissues for genetic and pathological testsYuichi Nakamura, Keisuke Tsuji, Takumi Shiraishi, et al.
Scientific Reports|March 24, 2022
Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancerHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Scientific Reports|March 17, 2026
Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancerKeita Hayakawa, Takashi Ueda, Masahiro Iehara, et al.
Scientific Reports|March 18, 2021
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancerHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 27, 2024
[Safety and Efficacy of Nivolumab plus Ipilimumab Therapy-Our Real World Experience]Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, et al.
Scientific Reports|April 5, 2024
The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapyHideya Yamazaki, Gen Suzuki, Koji Masui, et al.
World Journal of Urology|November 4, 2022
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patientsTakashi Ueda, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
European Journal of Radiology|February 15, 2025
Temporal Evolution of multiparametric magnetic resonance imaging findings following lesion-targeted focal microwave tissue coagulation for localized prostate cancerBunta Tokuda, Kaori Yamada, Nana Kozawa, et al.
Clinical and Translational Radiation Oncology|October 26, 2020
Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderlyHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Cancers|July 24, 2021
Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk FactorsHideya Yamazaki, Gen Suzuki, Koji Masui, et al.
Scientific Reports|April 24, 2023
Novel device for dividing core needle biopsy specimens to provide paired mirror image-like tissues for genetic and pathological testsYuichi Nakamura, Keisuke Tsuji, Takumi Shiraishi, et al.
Scientific Reports|March 24, 2022
Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancerHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Scientific Reports|March 17, 2026
Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancerKeita Hayakawa, Takashi Ueda, Masahiro Iehara, et al.
Scientific Reports|March 18, 2021
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancerHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 27, 2024
[Safety and Efficacy of Nivolumab plus Ipilimumab Therapy-Our Real World Experience]Ryuichi Morita, Takeshi Ishikawa, Toshifumi Doi, et al.
Scientific Reports|April 5, 2024
The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapyHideya Yamazaki, Gen Suzuki, Koji Masui, et al.
World Journal of Urology|November 4, 2022
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patientsTakashi Ueda, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.
Pageof 11